Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Cel-Sci completes another study in head and neck cancer

Dec. 29, 1999

Impressive early phase II clinical data reported for OvaRex in relapsed ovarian cancer

Dec. 29, 1999

Biomira's BLP25 liposome technology offers promise as cancer therapy

Dec. 29, 1999

SuperGen acquires equity interest in AVI BioPharma and negotiating rights to Avicine

Dec. 28, 1999

BLA filing for Campath announced

Dec. 27, 1999

AVI BioPharma's cancer vaccine enters phase III development

Dec. 27, 1999

DSMB recommends continuation of Allovectin-7 trials

Dec. 23, 1999

CeaVac trial reaches accrual goal; phase II trial will be expanded to phase III

Dec. 23, 1999

Transgene presents phase II data for cancer vaccine

Dec. 23, 1999

StressGen's new treatment for cervical dysplasia successfully completes phase I study

Dec. 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...